{
    "id": "469917c3-716f-4957-8f39-e44993f9561e",
    "indications": {
        "text": "enspryng indicated treatment neuromyelitis optica spectrum disorder ( nmosd ) adult patients anti-aquaporin-4 ( aqp4 ) antibody positive .",
        "doid_entities": [
            {
                "text": "neuromyelitis optica (DOID:8869)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8869"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "hepatitis b virus , tuberculosis , liver transaminase screening required first dose . ( 2.1 ) prior every , determine active infection . ( 2.2 ) recommended loading enspryng first three administrations 120 mg subcutaneous injection weeks 0 , 2 , 4 , followed maintenance 120 mg every 4 weeks . ( 2.2 ) full prescribing information important preparation instructions . ( 2.3 )",
        "doid_entities": [
            {
                "text": "hepatitis b (DOID:2043)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2043"
            },
            {
                "text": "hepatitis (DOID:2237)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2237"
            },
            {
                "text": "tuberculosis (DOID:399)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_399"
            }
        ],
        "orphanet_entities": []
    },
    "adverseReactions": "enspryng contraindicated patients : known hypersensitivity satralizumab inactive ingredients [ ( 5.4 ) ] active hepatitis b infection [ ( 5.1 ) ] active untreated latent tuberculosis [ ( 5.1 ) ]",
    "ingredients": [
        {
            "name": "SATRALIZUMAB",
            "code": "YB18NF020M",
            "drugbank_id": "https://go.drugbank.com/drugs/DB15762"
        },
        {
            "name": "HISTIDINE",
            "code": "4QD397987E",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_27570"
        },
        {
            "name": "ASPARTIC ACID",
            "code": "30KYC7MIAI",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_22660"
        },
        {
            "name": "ARGININE",
            "code": "94ZLA3W45F",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29016"
        },
        {
            "name": "POLOXAMER 188",
            "code": "LQA7B6G8JG",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32026"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        }
    ],
    "organization": "Genentech Inc.",
    "name": "Enspryng",
    "effectiveTime": "20250508",
    "indications_original": "ENSPRYNG is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.",
    "contraindications_original": "Hepatitis B virus, tuberculosis, and liver transaminase screening is required before the first dose. ( 2.1 ) Prior to every use, determine if there is an active infection. ( 2.2 ) The recommended loading dosage of ENSPRYNG for the first three administrations is 120 mg by subcutaneous injection at Weeks 0, 2, and 4, followed by a maintenance dosage of 120 mg every 4 weeks. ( 2.2 ) See Full Prescribing Information for important preparation and administration instructions. ( 2.3 )",
    "adverseReactions_original": "ENSPRYNG is contraindicated in patients with:\n                  \n                     A known hypersensitivity to satralizumab or any of the inactive ingredients [see Warnings and Precautions (5.4)]\n                     \n                     Active Hepatitis B infection [see Warnings and Precautions (5.1)]\n                     \n                     Active or untreated latent tuberculosis [see Warnings and Precautions (5.1)]",
    "drug": [
        {
            "name": "Enspryng",
            "drugbank_id": "https://go.drugbank.com/drugs/DB15762"
        }
    ]
}